New hope for Hard-to-Treat cancers: first human trial launches

NCT ID NCT06424665

Recruiting now Disease control Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Mar 08, 2026 · Last updated May 15, 2026 · Updated 9 times

Summary

This early-stage study tests a new drug called FZ-AD005 in people with advanced solid tumors, especially small cell lung cancer and large cell neuroendocrine carcinoma. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 162 adults aged 18 to 75 with measurable tumors and good overall health are eligible to join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR, SCLC(SMALL CELL LUNG CANCER) OR LCNEC (LARGE CELL NEUROENDOCRINE CARCINOMA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410013, China

Contact
Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200120, China

Contact
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR, SCLC(SMALL CELL LUNG CANCER) OR LCNEC (LARGE CELL NEUROENDOCRINE CARCINOMA) ADVANCED SOLID TUMOR, SCLC(SMALL CELL LUNG CANCER) OR LCNEC (LARGE CELL NEUROENDOCRINE CARCINOMA)